Reactions 1704, p284 - 2 Jun 2018 Pancreatitis and sarcoidosis : 3 case reports In a retrospective study of 53 patients, three patients [age and sex not stated], were described, who developed pancreatitis (2 patients) and sarcoidosis (1 patient) following treatment with nivolumab or pembrolizumab [routes and dosages not stated, not all durations of treatments to reactions onsets and outcomes stated]. All the three patients had cancer. Among these three patients, one patient received an injection of nivolumab and developed sarcoidosis seven weeks later. The patient’s sarcoidosis improved after corticosteroid therapy. Of the remaining two, one patient developed pancreatitis seven weeks after receiving first administration of nivolumab. The third patient developed pancreatitis following administration of pembrolizumab. Author comment: "[P]atients included in the present study had lipase increase related to anti-PD1 treatments. Two of the seven patients had pancreatitis imaging features, with abnormalities on CT scan. Programmed death receptor-1 blocking antibodies (anti-PD1) are a new standard of care in many cancer types. Patients benefit from improved survival but have the risk of immune-related adverse events (irAE) [Sarcoidosis-like syndrome]." Mekki A, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. European Journal of Cancer 96: 91-104, Jun 2018. Available from: URL: http://doi.org/10.1016/j.ejca.2018.03.006 - France 803322916 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera